News >

Nivolumab/Tivozanib Combo Shows Promise in mRCC

Published: Tuesday, Oct 08, 2019

Philippe Barthelemy, MD

Philippe Barthelemy, MD

Combining nivolumab (Opdivo) with the angiogenesis inhibitor tivozanib (Fotivda) led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma (mRCC), a preliminary open-label study showed.

Treatment-related adverse events (TRAEs) occurred frequently but were generally grade 1/2 in severity. The most common grade 3/4 TRAEs were hypertension (52%), laboratory abnormalities (32%, increased amylase, liver enzymes, alkaline phosphatase, gamma-glutamyl transferase, lipase), general disorders (12%, fatigue, systemic inflammatory response syndrome), and skin and related disorders (12%, palmar-plantar erythrodysesthesia, rash).


  1. Barthelemy P, Escudier B, Negrier S, et al. TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): Final results. Presented at 2019 ESMO Congress; September 27-October 2, 2019; Barcelona, Spain. Abstract 947P.
  2. Barthelemy P, Escudier B, Ravaud A, et al. TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC). Presented at: 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. Abstract 878P.
<<< View more from the 2019 ESMO Congress
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication